Cubist Systematic Strategies, LLC Anavex Life Sciences Corp. Transaction History

Cubist Systematic Strategies, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $257,004 - $507,380	50,993 New	50,993 $474,000
Q4 2022 Feb 14, 2023	SELL	$7.65 - $14.43 $44,920 - $84,732	-5,872 Reduced 4.68%	119,600 $1.11 Million
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $818,613 - $1.18 Million	91,979 Added 274.62%	125,472 $1.3 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $173,882 - $305,425	-23,787 Reduced 41.53%	33,493 $335,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $456,689 - $829,448	46,888 Added 451.19%	57,280 $705,000
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $67,520 - $93,240	-4,000 Reduced 27.79%	10,392 $180,000
Q3 2021 Nov 15, 2021	SELL	$16.82 - $25.75 $396,884 - $607,597	-23,596 Reduced 62.11%	14,392 $258,000
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $275,925 - $783,779	27,158 Added 250.77%	37,988 $868,000
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $55,991 - $174,687	10,830 New	10,830 $162,000
Q4 2020 Feb 16, 2021	SELL	$4.01 - $7.58 $46,852 - $88,564	-11,684 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.8 - $5.0 $23,305 - $30,665	-6,133 Reduced 34.42%	11,684 $53,000
Q2 2020 Aug 14, 2020	BUY	$2.62 - $5.2 $46,680 - $92,648	17,817 New	17,817 $88,000

152

26.5M

674K

811K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $443M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.